Altamira Therapeutics Ltd - שולי רווח נקי ממכירות CYTO

Altamira Therapeutics (CYTO) operates in a stable environment due to the humanitarian status of biomedicine, which neutralizes external conflicts. The net profit margin demonstrates effective cost management, where 0.00 reflects the baseline level of the metric. Profitability is based on the advantageous licensing of unique RNA platforms, although the operational component relies on third-party CRO and CMO contractors.
altamiratherapeutics.com (CYTO) - פילוחי מדדים ודוחות פיננסיים

The selection of high-quality issuers is based on a rigorous analysis of fundamental efficiency multiples. This metric determines the share of net profit in every dollar of revenue, reflecting the final profitability of the business. For Altamira Therapeutics (CYTO), low pricing power in the over-the-counter segment limits the growth of this value. The absence of patent income creates additional pressure on earnings. The net profit margin trend allows for an objective assessment of the company's operational resilience.